New epilepsy drug candidate takes first step in human safety trial
NCT ID NCT07156201
First seen Oct 31, 2025 · Last updated May 03, 2026 · Updated 26 times
Summary
This early-stage study tests a new medicine called ABS-1230 in 74 healthy adults to see if it is safe and how the body processes it. The drug is being developed for a rare form of epilepsy (KCNT1-related epilepsy). Participants receive either the drug or a placebo, and researchers monitor for side effects and measure drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KCNT1-RELATED EPILEPSY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Scientia Clinical Research
RECRUITINGSydney, New South Wales, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.